Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • B-Lymphocytes
  • Indoles
  • Leukemia, Hairy Cell
  • Proto-Oncogene Proteins B-raf
  • Sulfonamides

abstract

  • In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).

publication date

  • February 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1709919

PubMed ID

  • 29385376

Additional Document Info

start page

  • 449

end page

  • 459

volume

  • 378

number

  • 5